Daiichi Sankyo Co Ltd
4568: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥1,115.00 | Fzmwxqz | Wqzfrhvvk |
Initiating Coverage of Daiichi Sankyo With Narrow Moat and FVE of JPY 5,200
We initiate coverage on Daiichi Sankyo with a narrow moat rating, positive moat trend, and fair value estimate of JPY 5,200 per share. Daiichi is a global leader in antibody drug conjugates and its flagship HER2-targeting ADC, Enhertu, and its strong efficacy is changing the treatment landscape of HER2-expressing breast cancer.